% | $
Quotes you view appear here for quick access.

IntelliPharmaCeutics International Inc. Message Board

  • shavitmi shavitmi Nov 19, 2013 4:22 PM Flag


    Overall Analyst Rating:    BUY ( Up)Trade IPCI Now!

    Join SI Premium – FREE

    Intellipharmaceutics International Inc. (Nasdaq: IPCI), and Par Pharmaceutical, Inc. (NYSE: PRX) have added the development and commercialization of additional strengths of generic Focalin XR (dexmethylphenidate hydrochloride) for the U.S. market to their existing agreement, which applied to the development and commercialization of the 5, 10, 15 and 20mg strengths of generic Focalin XR.Under the terms of the expanded agreement, Intellipharmaceutics will receive an immediate cash payment from Par and will continue to receive a share of profits from future sales. According to Wolters Kluwer Health, U.S. sales of Focalin XR, used in the treatment of Attention Deficit Hyperactivity Disorder, were approximately $536 million for the 12 months ending June 2011.

3.1342+0.1242(+4.13%)10:53 AMEDT